Eversheds says Sun Pharmaceuticals deal represents opportunity in generics market
Eversheds partner Richard Lewis has commented on Sun Pharmaceuticals’ acquisition of Ranbaxy.
Lewis said: ‘This deal is a clear sign of further consolidation in the Indian generics market as companies look to increase market share, enhance growth opportunities and reduce costs.
‘As the country’s largest pharma company, it will now be particularly well placed to capitalise on the fast-growing Indian pharmaceuticals market.’
News from Eversheds
News from The Lawyer
Briefings from Eversheds
London Technology Week showcases London’s role as the digital capital of Europe and allows the industry’s top professionals to share ideas.
Capacity Market participants that wish to participate in this year’s auction need to ensure they are in a position to pre-qualify within the short pre-qualification window.
Analysis from The Lawyer
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe